JP2024541257A5 - - Google Patents

Info

Publication number
JP2024541257A5
JP2024541257A5 JP2024525577A JP2024525577A JP2024541257A5 JP 2024541257 A5 JP2024541257 A5 JP 2024541257A5 JP 2024525577 A JP2024525577 A JP 2024525577A JP 2024525577 A JP2024525577 A JP 2024525577A JP 2024541257 A5 JP2024541257 A5 JP 2024541257A5
Authority
JP
Japan
Prior art keywords
immune thrombocytopenia
pharmaceutically acceptable
acceptable salt
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541257A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/131278 external-priority patent/WO2023083281A1/zh
Publication of JP2024541257A publication Critical patent/JP2024541257A/ja
Publication of JP2024541257A5 publication Critical patent/JP2024541257A5/ja
Pending legal-status Critical Current

Links

JP2024525577A 2021-11-12 2022-11-11 キノリノン誘導体の免疫性血小板減少症を治療するための使用 Pending JP2024541257A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111340688.4 2021-11-12
CN202111340688 2021-11-12
PCT/CN2022/131278 WO2023083281A1 (zh) 2021-11-12 2022-11-11 一种喹啉酮衍生物治疗免疫性血小板减少症的用途

Publications (2)

Publication Number Publication Date
JP2024541257A JP2024541257A (ja) 2024-11-08
JP2024541257A5 true JP2024541257A5 (https=) 2026-01-15

Family

ID=86335130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525577A Pending JP2024541257A (ja) 2021-11-12 2022-11-11 キノリノン誘導体の免疫性血小板減少症を治療するための使用

Country Status (8)

Country Link
EP (1) EP4431097A4 (https=)
JP (1) JP2024541257A (https=)
KR (1) KR20240108437A (https=)
CN (1) CN118159269A (https=)
AU (1) AU2022386485A1 (https=)
CA (1) CA3236272A1 (https=)
MX (1) MX2024005200A (https=)
WO (1) WO2023083281A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118436647A (zh) * 2024-04-17 2024-08-06 湛江中心人民医院 沙利度胺的新应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012044936A1 (en) * 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
TW201822764A (zh) * 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
AU2018286247B2 (en) 2017-06-14 2021-12-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Syk inhibitor and use method therefor
WO2020119785A1 (zh) * 2018-12-14 2020-06-18 正大天晴药业集团股份有限公司 一种Syk抑制剂的盐及其结晶型

Similar Documents

Publication Publication Date Title
AU2012321110B2 (en) Combination treatment
CN107872975A (zh) 用于治疗恶心和呕吐的氨磺必利和其它止吐药的组合
JP2023535744A5 (https=)
JP2022514194A5 (https=)
JP2022550919A5 (https=)
KR20190016952A (ko) 스테로이드 용량의 감소 및 염증과 자가면역 질환의 치료를 위한 칸나비디올
JP2024541257A5 (https=)
JP2024531314A5 (https=)
JP2024540044A5 (https=)
JP2024543509A5 (https=)
RU2749857C1 (ru) Способ борьбы со средним и наружным отитом
RU2024114849A (ru) Применение производного хинолинона в лечении иммунной тромбоцитопении
WO2023083281A1 (zh) 一种喹啉酮衍生物治疗免疫性血小板减少症的用途
WO2020183020A1 (en) Capsid assembly modulator solid formulation
JP2022538898A5 (https=)
US20100184732A1 (en) Method of long-term treatment of graft-versus-host disease using topical active corticosteroids
AU2011202639A1 (en) Compositions and methods for treating myelodysplastic syndrome
WO2025208442A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
EP2392329B1 (en) Compositions for use in treating myelodysplastic syndrome
JP2025511403A5 (https=)
CN107519176A (zh) 防治运动病、梅尼埃病的药物及莫扎伐普坦的医药用途
JP7653712B2 (ja) 高リスク骨髄異形成症候群の治療薬
TW202120092A (zh) 化合物用於預防或治療移植物抗宿主病的用途
CN108478581A (zh) 防治运动病、梅尼埃病的药物及托伐普坦的医药用途
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer